Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677376 · ClinicalTrials.gov registry record
Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 7
- Enrollment target
NCT02677376: Completed study, sponsored by University of Wisconsin, Madison.
NCT02677376 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02677376 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
Primary Outcome
To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
Interventions
- OTHER 18F-Sodium Fluoride (NaF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-27 |
| Est. Completion | 2020-01-03 |
What the finished NCT02677376 record still lists
NCT02677376 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 18F-Sodium Fluoride (NaF) is the first listed.
NCT02677376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02677376 about?
NCT02677376 is a clinical study titled "Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC". To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
What is the current status of trial NCT02677376?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2016-06-27. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT02677376?
The interventions under investigation include: 18F-Sodium Fluoride (NaF) (OTHER).
Who is sponsoring clinical trial NCT02677376?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI